Related references
Note: Only part of the references are listed.Comprehensive assessment of amino acid substitutions in the trimeric RNA polymerase complex of influenza A virus detected in clinical trials of baloxavir marboxil
Takashi Hashimoto et al.
INFLUENZA AND OTHER RESPIRATORY VIRUSES (2021)
Pharmacokinetic and pharmacodynamic analysis of baloxavir marboxil, a novel cap-dependent endonuclease inhibitor, in a murine model of influenza virus infection
Yoshinori Ando et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
Evaluating the fitness of PA/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret model
Leo Y. Y. Lee et al.
PLOS PATHOGENS (2021)
Influenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are fit and transmit through respiratory droplets
Masaki Imai et al.
NATURE MICROBIOLOGY (2020)
Duration of fever and PA/I38X-substituted virus emergence in patients treated with baloxavir in the 2018-2019 influenza season
Hideyuki Ikematsu et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2020)
Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial
Michael G Ison et al.
LANCET INFECTIOUS DISEASES (2020)
Duration of fever and symptoms in children after treatment with baloxavir marboxil and oseltamivir during the 2018-2019 season and detection of variant influenza a viruses with polymerase acidic subunit substitutions
Reiko Saito et al.
ANTIVIRAL RESEARCH (2020)
Overview of Current Therapeutics and Novel Candidates Against Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections
Mohammad Amin Behzadi et al.
FRONTIERS IN MICROBIOLOGY (2019)
Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018
Emi Takashita et al.
EUROSURVEILLANCE (2019)
Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons
Larisa V. Gubareva et al.
EUROSURVEILLANCE (2019)
Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection
Keita Fukao et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Population Pharmacokinetic and Exposure-Response Analyses of Baloxavir Marboxil in Adults and Adolescents Including Patients With Influenza
Hiroki Koshimichi et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2019)
Human-to-Human Transmission of Influenza A(H3N2) Virus with Reduced Susceptibility to Baloxavir, Japan, February 2019
Emi Takashita et al.
EMERGING INFECTIOUS DISEASES (2019)
Drugs for Influenza Treatment: Is There Significant News?
Nicola Principi et al.
FRONTIERS IN MEDICINE (2019)
Influenza virus-related critical illness: prevention, diagnosis, treatment
Eric J. Chow et al.
CRITICAL CARE (2019)
Susceptibility of Influenza A, B, and D Viruses to Baloxavir
Vasiliy P. Mishin et al.
EMERGING INFECTIOUS DISEASES (2019)
Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil
Keiichi Taniguchi et al.
SCIENTIFIC REPORTS (2019)
Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil
Shinya Omoto et al.
SCIENTIFIC REPORTS (2018)
Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents
Frederick G. Hayden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit
Takeshi Noshi et al.
ANTIVIRAL RESEARCH (2018)
Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemic
P Ward et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants
LV Gubareva et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza - A randomized controlled trial
JJ Treanor et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
Share Paper
